Sulfur mustard (SM) is a chemical warfare agent leading to severe blistering of skin and mucosal surfaces. and as a long-term effect, to an increased risk for malignancies. At the molecular level, SM acts as a bifunctional alkylating agent, leading to DNA mono-adducts and di-adducts. This review is focussed on the role ofpoly(ADP-ribosyl)ation in the cell and tissue responses to SM-induced damage and potential role of inhibitors of poly(ADP-ribosyl)ation as therapeutic agents for SM injury.
Introduction
Sui fur mustard (2.2'-dichlorodiethylsulfide; SM) is a highly toxic and mutagenic warfare agent classified as a weapon of mass destruction. The long history ofSM begins with its synthesis in the 19th century. It was recognised early on that SM is a potent blistering agent. Along with phosgene and chlorine. it started the era of chemical weapons on the battlefields of World War I. Thereafter. it entered permanently to the international military arsenal and it is still regarded a threat for modern societies (Kehe and Szinicz. 2005) . While the production of SM does not require specialised technology. the danger of terrorist attack against the civilian population is considerable. On the other hand. apart from the purposeful attack. there is a risk of accidental exposure to SM connected with inappropriate disposal of old depots (Geraci. 2008) . Paradoxically. SM has found applications in medicine. The original compound has been in use for some time for the treatment of psoriasis Uanouchek et al.. 1987) . During World War 11. a military research group investigated the effects of SM and its nitrogen relatives on rapidly dividing cells. These efforts resulted in medical applications of alkylating mustard compounds. The first therapy of leukaemia with nitrogen mustard was highly effective (Goodman et aI., 1984) . Thus, a number of sulfur and nitrogen mustard derivatives such as cyclophosphamide, chlo-
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rambucil and melphalan are currently used as common anti-cancer drugs. In addition, recognition of SM as an immunosuppressant compound prompted studies on chemical immunosuppression. These studies finally paved the way for organ transplantation (Patel. 2006) . As soon as SM was first used as a warfare agent, research aimed at the development of an effective antidote was launched. Despite extensive investigation, the expected progress has been rather disappointing so far. Different clinical approaches including application of antioxidants, scavengers, anti-inflammatory drugs and protease inhibitors have been tested for treatment of the acute injuries but none ofthem gave full protection against formation of delayed pathology (Casillas et aI., 2000) . This review is focussed on the role of poly(ADP-ribosyl)ation in the cell and tissue responses to SM-induced damage. Poly(ADP-ribosyl)ation is one of the most drastic post-translational protein modifications and plays a key role in a wide range of biological processes, including DNA repair, transcriptional regulation and cell death signalling. Early studies with first-generation inhibitors of poly(ADP-ribosyl)ation have already revealed some promising therapeutic potential in SM skin injury (Cowan et al.. 2003) . The availability of new, more effective inhibitors brings it back to the centre of interest.
Cellular targets of sulfur mustard
Exposure to SM is seldom fatal but leads to severe injuries. demanding long-term medical support. The most affected organs First publ. in: Toxicology 263 (2009), 1, pp. 20-25 Konstanzer ing in direct contact with the toxic liquid or vapour. SM is a powerful blistering agent. The formation of thin-walled blisters is preceded by an asymptomatic latent period of several hours, followed by itching, pain and erythema. Cytotoxicity is primarily apparent in basal keratinocytes but with time cellular degeneration can be observed within all layers of skin. The separation of epidermis and dermis, which underlies blister formation, is accompanied by local inflammation. Progression of the lesions and the degree of blistering and necrosis is depending on dose of SM delivered (Evison et aI., 2002; Ruff and Dillman, 2007) . SM is a bifunctional alkylating agent, reacting readily with most cellular macromolecules including proteins ahd nucleic acids. The reaction with DNA leads to· rapid formation of mono-and diadducts. The majority of DNA alkylation consists of adducts at the N-7 pOSition of guanine and N-3 position of adenine, accounting for 61 and 16% of total alkylations, respectively (Ludlum et aI., 1994) . DNA di-adducts, on the other hand, represent about 15% of SM-induced DNA lesions and are formed by reaction of one SM molecule with N-7 positions of two guanines. Di-adducts occur within the same or complementary DNA strands, yielding intra-and interstrand cross-links, respectively. The formation of intrastrand cross-links is favoured (Ludlum and Papirmeister, 1986) .
SM is a relatively poor inducer of DNA strand breaks. Mol et al. quantified the number of DNA single strand breaks and/or alkali-labile sites in cultured human epidermal keratinocytes by using the alkaline elution method. The induction of DNA singlestrand breaks, measured immediately after 30 min exposure, was dose-dependent. Assuming a linear dose-effect relationship, it was calculated that 1 f.LM SM induces approximately 0.05 breaks/lOg Da of DNA, which corresponds to 0.2 Gy of ionizing radiation. For comparison, under the same conditions, the number of interstrand cross-links was estimated to be 0.12 cross-links/lOg Da of DNA (Mol et aI., 1993) . Further incorporation of DNA strand breaks might be initiated during the repair process of DNA alkylations. The dependence of strand breaks formation on apurinic endonuclease after SM exposure was shown (Papirmeister et aI., 1985) . These DNA strand breaks are in turn recognised by PARP-l (see below).
Although the DNA-damaging properties of SM are essential for its toxicity, the reactivity with other macromolecules should not be neglected. It was found that cytoskeletal changes, such as loss of stress fibres and rounding of the cells, proceed in endothelial cells after SM treatment even in absence of the cell nucleus, i.e. in cytoplasts. However, in contrast to endothelial cells, endothelial cytoplasts did not show the hallmarks of apoptosis such as caspase-3 activation and externalisation of phosphatidylserine (Lodhi et aI., 2001) . Thus, DNA alkylation seems to be responsible for triggering of apoptosis but not for all of the cytotoxic effects of SM.
The interaction ofSM with cellular antioxidants system deserves special interest. SM reacts readily with cellular thiols such as glutathione (GSH). The depletion of intracellular levels of GSH was reported in cell culture systems and in vivo models (Vijayaraghavan et aI., 1991; Pant et aI., 2000; Kumar et aI., 2001) . Furthermore, the depletion of key antioxidant enzymes such as superoxide dismutase, catalase and glutathione peroxidase was observed (Husain et aI., 1996; jafari, 2007) . The exhaustion of the cellular antioxidant system results in accumulation of endogenous reactive oxygen species (ROS) and subsequent secondary damage of macromolecules, including lipid peroxidation and DNA damage (Paromov et aI., 2007) . The reaction with DNA would lead to further activation ofPARP-1.
Poly(ADP-ribose) polymerase-1: a protein for all occasions
Poly(ADP-ribosyl)ation is a post-translational protein modification induced by genotoxic treatment in multicellular organisms. The reaction is catalysed by the family of poly(ADP-ribose) polymerases (PARPs) encoded in humans by more than a dozen different genes. Two family members, i.e. PARP-l and PARP-2, have been shown to be activated by DNA strand breaks. By using NAD+ as a substrate, PARPs build up homopolymeric branched chains of ADP-ribose [poly(ADP-ribose); PAR] of different length that are covalently bound to "acceptor" proteins at glutamic and aspartic acid or lysine residues. PAR may comprise up to 200 ADP-ribose units, coupled with each other via unique ribose (1" ~ 2') ribose bonds, and displays multiple branching points each 20-50 residues resulting from the formation of ribose (1'" ~ 2") ribose linkages. Apart from the covalent modification of acceptor proteins, PAR has also been shown to interact non-covalently with proteins. A specific PAR-binding motif has been identified in wide range of proteins involved in DNA repair and cell cycle checkpoints (Pleschke et aI., 2000) . The non-covalent PAR interaction is dependent on polymer chain length and the nature of the acceptor protein. For example, both short and long polymers can interact with the tumour suppressor protein p53, while under the same experimental conditions the nucleotide excision repair protein XPA binds exclusively long chains (Fahrer et aI., 2007) .
Most attention has been focus sed on PARP-l IEC 2.4.2.30], which is the best-characterised family member and also displays the highest level of enzymatic activity. PARP-l is a constitutively expressed 113-kDa nuclear protein. In the absence of DNA damage, it has a very low basal activity but becomes rapidly activated by over lOO-fold in presence of DNA strand breaks. PARP-l is able to bind directly to single as well as to double-strand breaks. However, several groups have provided evidence that PARP-l also recognises structural changes in DNA other than strand breaks, including distortions in DNA helical backbone and three and four-way junctions. Upon treatment of cells with DNA-damaging agents, 90% of cellular PAR is synthesized by PARP-1. The major"acceptor" protein (i.e. protein undergoing covalent modification with PAR) is PARP-l itself, in the context of the so-called automodification reaction, but many other acceptor proteins have been described, including p53, both subunits of NF-KB, histones, DNA topoisomerases and the catalytic subunit of DNA-dependent protein kinase (DNA-PK). Due to the high negative charge of PAR, this modification significantly alters the physical and biochemical properties of the modified proteins including their DNA-binding affinity, and it is likely that such alteration will have a regulatory function concerning the interaction with other proteins.
A complete description of the multifaceted biological functions of PAR is beyond the scope of this review. Instead we focus here on those aspects that have a putative impact on the processing of SM lesions, i.e. the regulation of DNA repair, cell death and transcription. The biological function of PARP-l that is established best is the coritribution in the maintaining of survival and genomic integrity under genotoxic stress. PARP-l becomes activated within minutes upon treatment with DNA damaging agents and promotes survival of cells. Cells and mice lacking functional PARP-l are hypersensitive to a number of DNA-damaging agents such as ionizing radiation, alkylating agents or oxidants. The protective action of PARP-l was initially ascribed to regulation of base-excision repair pathway (BER). The current view, however, assumes involvement of PARP-l at different stages of strand break repair: recognition of damage, local relaxation of the chromatin by direct modification of the histones and finally the assembly of repair protein complex by noncovalent interaction with PAR.
Alternatively, PARP-1 has been ;viewed to act as a switch between long and short-patch BER pathway, depending on the availability ofATP.
Recently, it has been shown that PARP-1 plays a role beyond BER. pARP-1 is implicated in double-strand break repair by at least two different pathways. Upon binding to double-strand breaks PARP-1 initiates the so-called backup non-homologous end joining pathway (B-NHEJ). B-NHEJ operates independently of classic NHEJ but is dependent on XRCC1/ligase III (Rosidi et aI., 2008; Wu et aI., 2008) . Furthermore, a link between PARP-1 and the "Ataxia-telangiectasia mutated" (ATM) protein was established. These proteins have been known for a long time to operate in different, independent DNA strand-break repair pathways. Recent studies, however, revealed that ATM noncovalently interacts with PAR. Moreover, the recruitment ofMrell and NBS-1 to the damage site and the ATM response to double-strand breaks is delayed by PARP-1 inhibition. Altogether the data suggest an upstream role of PAR in ATM regulation (Haince et aI., 2007 (Haince et aI., , 2008 .
PARP-1 has implications in apoptotic and necrotic cell death pathways. The involvement of PAR in an intrinsic apoptotic pathway was described by the Dawson group. Upon treatment with the alkylating agent MNNG, PARP-1 becomes activated and undergoes automodification. The enzymatic degradatio'n of polymers produces free PAR chains, which act as a death signal after translocation to mitochondria, by inducing AIF release and ca spa se-independent apoptosis. In turn, the specific cleavage of PARP-1 by caspase-3/7 and generation of 89 and 24 kDa fragments have been extensively used as a biochemical marker of caspase-dependent apoptosis. Caspase-mediated cleavage of PARP-1 leads to loss of its catalytic activity and inactivation of its pro-survival function but preserves .the depletion of NAD+ that would ensue as a result of sustained PARP-1 activity stimulated by large numbers of strand breaks. The over-activation of PARP-1 and consequent NAD+ crisis leading to massive necrotic cell death has been demonstrated to play a major role in a wide variety of pathophysiological conditions, including ischemia-reperfusion damage and a wide range ofinflammatory conditions. This scenario has also implications for SM skin injury.
Interesting results concerning PARP-1 function have been obtained using the Parpl knockout mice model. Surprisingly, animals were resistant to multiple inflammatory disorders including endotoxin-induced septic shock. The typical up-regulation of a sub~ set ofinflammatory mediators mediated by NF-KB gene expression, such as TNF-a, IFN-y and iNOS, was impaired in Parp-l-I -animals. It has been shown that PARP-1 physically interacts with NF-KB and is indispensable for its transcriptional activation. Remarkably, there is a debate if NF-KB activation is dependent on PARP-1 enzymatic activity or just on PARP-1 protein expression. In any event, regulation of transcription by PARP-1 is not limited to NF-KB. Indeed, numerous physical and functional interactions with stressinducible transcription factors including AP-1 and HIF-1 a (Elser et aI., 2008) have been described.
Poly(ADP-ribose) in sulfur mustard injury
SM exposure is connected with induction of DNA strand breaks by three possible mechanisms: (i) direct reaction of the compound with DNA; (H) strand breaks as intermediates during the process of repair of DNA alkylation; or (Hi) secondary increase in cellular ROS level. PARP-1 is a first-line protein involved in the cellular response to DNA strand breaks and becomes immediately activated upon treatment with genotoxic agents such as ionizing radiation or alkylating agents. The activation of PARP-1 in the processing of SM-induced damage is, therefore, not surprising. The first data connecting PARP-1 with SM exposure were reported over two decades ago by Papirmeister et al. (1985) . In their very attractive biochemical hypothesis they linked early DNAdamaging events with late pathology of the skin. The proposed mechanism assumed that the massive induction of DNA strand breaks in enzymatic processing of SM DNA adducts would lead to activation of PARP-1 and consequent depletion of cellular NAD+. This in turn would result in a collapse of ATP production, followed by protease release and blister formation. The model was strongly supported by in vitro and in vivo experiments. The direct induction of DNA strand breaks upon SM exposure was not observed. However, the DNA fragmentation appeared if SM-treated DNA was incubated with recombinant bacterial apurinic endonuclease, consistent with a role of strand breaks as DNA repair intermediates. The NAD+ level and pathological changes were followed in mice grafted with human skin as a model system. SM induced a time and dose-dependent decrease of NAD+ concentration. The reduction was marked already by 2 h after treatment and reached a maximum 2 h later. The depletion was correlated with the severity of skin injury. Mild injury was associated with little initial decrease in NAD+ level and with recovery back to control levels 18 h after treatment. The decrease in NAD+ level below 25% of control was irreversible and correlated with severe injury. The NAD+ depletion could be prevented by pre-treatment with the PARP inhibitor 3-aminobenzamide.
PARP-1 activation and severe NAD+ depletion have independently been confirmed in different cell systems including primary leukocytes (Meier et aI., 1987) , keratinocytes and endothelial cells (Mol et aI., 1989; Hinshaw et aI., 1999) and also in animal models (You rick et aI., 1991; Zhang et aI., 1995) . In all cell culture models, SM treatment induced a time and dose-dependent decrease in NAD+ level. The depletion was observed up to 2 h post-treatment time. The degree of NAD+ loss was correlated with the SM dose applied. In addition to determinations ofNAD+ level, Hinshaw et al. measured PARP-1 activity in permeabilised cells by incorporation of radioactive-labelled NAD+. PARP-1 activity in keratinocytes and endothelial cells displayed a mirror image to NAD+ concentration. PARP-1 activation was observed 2 h after treatment with 500 J.1M SM and persisted up to 5 h after treatment (Hinshaw et aI., 1999) .
Based on the above, one may expect that if severe NAD+ consumption could be prevented this would protect against cytotoxicity of SM. The availability of cell-permeable PARP-1 inhibitors made it possible to test this hypothesis. Nevertheless, the results obtained in cell culture models appeared to be rather disappointing. While the cellular NAD+ pool could indeed be preserved by treatment of cells with PARP-1 inhibitor 3-aminobenzamide (Papirmeister et aI., 1985; Meier et aI., 1987) , this did not have any effect on total cell survival. Instead, PARP-1 inhibition favoured induction of apoptosis over necrosis. Inhibition of PARP-1 resulted in increased caspase activation, PARP-1 apoptotic cleavage and DNA laddering (Meier et aI., 2000; Kehe et aI., 2007; Steinritz et aI., 2007) . It should be noted that a protective effect of the PARP inhibitors 3-aminobenzamide or niacinamide against cell death caused by SM was shown for human Iymphocytes (Meier and Johnson, 1992; Meier, 1996) . In both reports, however, cytotoxicity was measured by dye exclusion. By this method only necrotic cells are scored as dead cells. The results, therefore, did not contradict other studies but are in agreement with the notion that PARP-1 inhibition can rescue cells from necrotic cell death. It has been suggested that a switch between apoptosis and necrosis might be dependent on cellular ATP content. Apoptosis is energy-dependent, whereas necrosis is not, and can be occur without ATP supply. According to this view, activated PARP-1 would use up the NAD+ pool resulting in impairment of ATP synthesis. However, this assumption does not seem to be realistic in the case of SM treatment. ATP concentration decreased significantly in keratinocytes but only after high-dose treatment with 1 mM SM. Lower-dose exposure did not have an impact on ATP levels despite affecting cell viability (Hinshaw et aI., 1999; Kehe et aI., 2007) . At this point it is worth noting that the "classical" effect of PARP inhibitors applied to proliferating cells exposed to low doses of monofunctional alkylating agents or ionizing radiation is the enhancement of cell killing, which can be explained by blockage of base-excision repair and therefore accumulation of DNA damage to lethal levels (Biirkle, 2005) . The fact that such phenomenon has not been reported for (low-dose) SM treatment could mean either that base-excision repair is not of functional importance for the removal of SM-induced DNA damage or that the effect on BER is covered up by other effects of PARP inhibition such as changes in NAD+ metabolism as discussed above. Presently available data do not allow distinguishing between these possibilities.
While the cytoprotective effects of PARP-l inhibition in vitro were of limited magnitude, work on animal models revealed that it might have therapeutic value in the treatment of skin injuries. Pre-treatment with the PARP inhibitor niacinamide reduced microvesicle formation by 50% in hairless guinea pigs cutaneously exposed to SM (Yourick et aI., 1991) . It should be noted, however, that niacinamide may have a dual function, i.e. it also serves as a precursor to NAD+, which can render interpretation of the biological effects difficult. On the other hand, PARP inhibitors also emerged as potential therapeutic candidates in the battle drug-screening program initiated by US Army Medical Research Institute of Chemical Defence. The study included nearly 400 compounds tested in the mouse ear model for skin injury. Among 19 drugs that revealed reduced histopathological changes by >50%, three different compounds were recognised as PARP inhibitors, i.e. 3-(4'-bromophenyl)ureidobenzamide, benzoylene urea and 4-amino-l-naphtol hydrochloride (Cowan et aI., 2003) . There are two possible explanations for the protective effect of PARP-l inhibitors in vivo. First the reduction of necrotic cell death would result in decrease of protease activity and inflammation caused by uncontrolled cell disruption. Second, the direct interference with inflammatory signalling could mitigate secondary tissue damage resulting from inflammation.
The involvement of PARP-l in cell death regulation after SM exposure attracted most attention of researchers. The other possible consequences of PARP-l activation, including its primarily role in the DNA repair process, were hardly investigated. A set of studies were designed to reveal the action of PARP-l in DNA strand break repair (Bhat et aI., 2000 (Bhat et aI., , 2006a . Primary keratinocytes displayed rapid phosphorylation and activation of DNA ligase I after SM treatment. This process was dependent on DNA-PK activity. Interestingly, the half-life of activated DNA ligase I increased in the presence of 3-aminobenzamide from 1.3 to 4.3 h. Nevertheless, the experimental system used by the authors does not provide direct evidence for the involvement of PARP-l in SM DNA damage repair. Furthermore, comparisons were made between primary normal human keratinocytes and immortalised stably transfected cells with an inducible PARP-l anti-sense construct. When compared to primary wild-type cells, PARP-l deficient cells displayed impaired induction of DNA ligase I phosphorylation by SM. However, one has to keep in mind that the basal level of specific activity ofligase I in these cells was five times higher than in primary PARP-l wild type cells. Furthermore, it was shown that the DNA repair rate in inducible PARP-l-deficient cells was about 60-70% lower than in primary keratinocytes. On the other hand, the repair rate in induced and uninduced anti sense PARP-l cells did not differ. The differences in repair reaction velocity were apparently resulting from cell type specificity and not PARP-l status. Anyway, the fast activation of PARP-l indicates that the enzyme is able to recognise DNA damage induced by SM. The possible involvement of PARP-l in facilitating DNA repair is definitively worth of more detailed investigation.
Perspectives
The current renaissance of PARP-l inhibitors in cancer chemotherapy, either in combination with alkylating agents (Thomas et aI., 2007) or as a monotherapy against tumours that are deficient in homologous recombination (Bryant et aI., 2005; Farmer et aI., 2005) opens new avenues for treatment of SM injury. Initial studies with PAPR-l inhibitors have already revealed a potential in management of SM skin injury. There is now a new generation of inhibitors available, which is over 100 times more potent than the classical ones, has improved pharmacokinetic properties and higher specificity. Several PARP inhibitors are undergoing clinical trials as drugs for cancer treatment and their pharmacodynamic properties are intensely monitored. If approval for medical use were obtained it could make available a "ready to use" drug that might soon be applied in SM therapy (Zaremba and Curtin, 2007) .
There is, however, one important point to consider: SM is a known mutagen and carcinogen. In this context, inhibition ofPARP-1 Ihight act as double-edged sword (Fig. 1) . We do know that PARP-l is; ,ctivated upon SM-induced DNA damage. Its participation in DNA repair processes upon SM exposure is so far not clear. PARP-l is a key player in repair of DNA damage induced by simple alkylatiflgagents and ionizing radiation. PARP-l inhibition in combination with alkylating agent treatment leads to increased genomic instability and chromosome damage (Biirkle, 2005) . The influence of pARP-l inhibition on SM-induced mutagenesis should therefore be investigated in order to assess the safety of PARP inhibitors as potential therapeutics.
Finally, the role of PARP-l in regulation of transcription, in particular in the expression of inflammatory cytokines. is still an under-researched field. Keratinocytes have been shown to respond to SM exposure with production of inflammatory cytokines incIudingIL-l, IL-6, IL-8 and TNF-a. Cytokine production was blocked by inhibition of p38 kinase (Dillman et aI., 2004) . Parallel to MAPK activation. keratinocytes also activate the canonical NF-KB pathway (Rebholz et aI., 2008) . PARP-l, on the other hand. is an important coactivator of NF-KB in lipopolysaccharide-induced transcription of genes encoding inflammatory cytokines. Therefore, the functional interplay between PARP-l and NF-KB in SM-induced inflammation appears to be another promising aspect of future research on PARP inhibitors as a potential treatment for SM injury.
